SPYGLASS PHARMA, INC.
NASDAQ: SGP (SpyGlass Pharma, Inc.)
Kemas kini terakhir: 8 jam lalu27.07
-0.58 (-2.10%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | SpyGlass Pharma, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.83 |
|
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nea Management Company, Llc | 30 Jun 2026 | 7,392,301 |
| Sands Capital Alternatives, Llc | 30 Jun 2026 | 2,500,012 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 2,109,953 |
| Vestal Point Capital, Lp | 30 Jun 2026 | 670,000 |
| Deerfield Management Company, L.P. | 30 Jun 2026 | 550,000 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 131,586 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |